Market revenue in 2023 | USD 50.7 million |
Market revenue in 2030 | USD 60.7 million |
Growth rate | 2.6% (CAGR from 2023 to 2030) |
Largest segment | Product registration & clinical trial applications |
Fastest growing segment | Legal representation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory consulting, Legal representation, Regulatory writing & publishing, Product registration & clinical trial applications, Regulatory Submissions, Regulatory Operations, Other services |
Key market players worldwide | Genpact Ltd, Criterium Inc., Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, Labcorp Drug Development, FREYR Battery Inc, Cencora Inc, Pharmexon, QVigilance, BlueReg Group, ZEINCRO Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs outsourcing market will help companies and investors design strategic landscapes.
Product registration & clinical trial applications was the largest segment with a revenue share of 26.04% in 2023. Horizon Databook has segmented the UAE regulatory affairs outsourcing market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, regulatory submissions, regulatory operations, other services covering the revenue growth of each sub-segment from 2018 to 2030.
Currently, UAE is the third largest market for Regulatory affairs in the MEA region since most market players are dependent on imports. Medical device regulations in the country are based on Australian TGA, EU, and the U.S. regulations.
Products with approval from the Canadian, Australian, EU, and the U.S. regulatory agencies are eligible for a short registration process in the UAE. The UAE Government is focused on attracting innovative drug manufacturers by 2021, with double the number of local companies producing patented drugs.
The country has a short drug registration system for both innovator and generic drugs approved by the U.S. FDA. Some of the examples of fast-tracked drugs in UAE are AbbVie’s Viekirax, Exviera (dasabuvir), and Eli Lilly's Trulicity.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE regulatory affairs outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into UAE regulatory affairs outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account